SEC Form 4Coverage since Aug 27, 2025Open-market trades only
$TVTX insider trading
Over the last 12 months, Travere Therapeutics insiders reported no purchases and 54 sales totaling $39.4M across SEC Form 4 filings. 85% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $39.4M 54 events
- Events · 12m
- 54 Form 4 filings, grouped
- Insiders · 12m
- 11 distinct reporters
- 10b5-1 share
- 85% of events, not dollars
Side
Price · $TVTX · 3Mvia TradingView
Top insiders · 12m
REED ELIZABETH EChief Legal Officer and GC9× · $4.9M
Dube Eric MCHIEF EXECUTIVE OFFICER7× · $16.0M
Heerma PeterCHIEF COMMERCIAL OFFICER6× · $1.1M
Cline Christopher R.CHIEF FINANCIAL OFFICER6× · $1.5M
Inrig JulaCHIEF MEDICAL OFFICER6× · $2.4M
All insider trades
50 of 56 events
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | Meckler Jeffrey AD | ▼ Sale | 20,000 | $67.31 | $1.3M | -17.9% | plan · 4 tranches |
| Sep 2, 2026 | Cline Christopher R.CHIEF FINANCIAL OFFICER · O | ▼ Sale | 642 | $66.37 | $43K | -0.5% | — |
| Aug 18, 2026 | LYONS GARY AD | ▼ Sale | 10,000 | $63.28 | $633K | -14% | plan · 5 tranches |
| Jun 12, 2026 | Coughlin TimothyD | ▼ Sale | 10,000 | $50.07 | $501K | -15.1% | plan |
| Jun 12, 2026 | Baynes Roy D.D | ▼ Sale | 4,500 | $50 | $225K | -9.8% | plan |
| May 6, 2026 | Cline Christopher R.CHIEF FINANCIAL OFFICER · O | ▼ Sale | 2,491 | $46.31 | $115K | -2.1% | plan · 2 tranches |
| May 6, 2026 | Inrig JulaCHIEF MEDICAL OFFICER · O | ▼ Sale | 22,485 | $45.15 | $1.0M | -16.6% | plan · 3 tranches |
| May 6, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER · O·D | ▼ Sale | 22,500 | $43.95 | $989K | -4.9% | plan |
| May 6, 2026 | ROTE WILLIAM E.Chief Research Officer · O | ▼ Sale | 2,763 | $43.95 | $121K | -2.3% | plan |
| May 6, 2026 | REED ELIZABETH EChief Legal Officer and GC · O | ▼ Sale | 24,250 | $45.06 | $1.1M | -18.7% | plan · 3 tranches |
| May 5, 2026 | Heerma PeterCHIEF COMMERCIAL OFFICER · O | ▼ Sale | 2,174 | $46.65 | $101K | -1.5% | — |
| May 5, 2026 | Baynes Roy D.D | ▼ Sale | 4,500 | $46.65 | $210K | -10.7% | plan |
| May 4, 2026 | Meckler Jeffrey AD | ▼ Sale | 8,000 | $45 | $360K | -8.4% | plan |
| May 1, 2026 | Baynes Roy D.D | ▼ Sale | 9,750 | $44.22 | $431K | -20.6% | plan |
| Apr 22, 2026 | ROTE WILLIAM E.Chief Research Officer · O | ▼ Sale | 9,100 | $39.09 | $356K | -7.4% | plan |
| Apr 15, 2026 | Cline Christopher R.CHIEF FINANCIAL OFFICER · O | ▼ Sale | 8,327 | $41.91 | $349K | -6.6% | plan · 4 tranches |
| Apr 15, 2026 | Inrig JulaCHIEF MEDICAL OFFICER · O | ▼ Sale | 8,233 | $42.01 | $346K | -6.9% | plan · 2 tranches |
| Apr 15, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER · O·D | ▼ Sale | 64,000 | $41.09 | $2.6M | -12.9% | plan · 3 tranches |
| Apr 15, 2026 | REED ELIZABETH EChief Legal Officer and GC · O | ▼ Sale | 51,500 | $41.29 | $2.1M | -32.9% | plan · 4 tranches |
| Apr 14, 2026 | Calvin SandraSVP, CHIEF ACCOUNTING OFFICER · O | ▼ Sale | 21,977 | $41.07 | $903K | -34.2% | plan |
| Apr 14, 2026 | Baynes Roy D.D | ▼ Sale | 32,750 | $41.29 | $1.4M | -46.6% | plan · 2 tranches |
| Apr 14, 2026 | LYONS GARY AD | ▼ Sale | 8,000 | $41.07 | $329K | -12.2% | plan |
| Apr 14, 2026 | Heerma PeterCHIEF COMMERCIAL OFFICER · O | ▼ Sale | 7,215 | $41.93 | $303K | -4.9% | — |
| Apr 6, 2026 | Baynes Roy D.D | ▼ Sale | 10,000 | $33 | $330K | -21.1% | plan |
| Apr 1, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER · O·D | ▼ Sale | 60,000 | $30.93 | $1.9M | -12.2% | plan · 2 tranches |
| Apr 1, 2026 | REED ELIZABETH EChief Legal Officer and GC · O | ▼ Sale | 10,000 | $30 | $300K | -8.7% | plan |
| Mar 16, 2026 | REED ELIZABETH EChief Legal Officer and GC · O | ▼ Sale | 10,000 | $28.09 | $281K | -8.7% | plan |
| Feb 20, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER · O·D | ▼ Sale | 60,000 | $30.1 | $1.8M | -12.2% | plan |
| Feb 17, 2026 | REED ELIZABETH EChief Legal Officer and GC · O | ▼ Sale | 10,000 | $27.83 | $278K | -8.7% | plan · 2 tranches |
| Feb 4, 2026 | Cline Christopher R.CHIEF FINANCIAL OFFICER · O | ▼ Sale | 1,745 | $32.19 | $56K | -1.5% | plan · 2 tranches |
| Feb 4, 2026 | Inrig JulaCHIEF MEDICAL OFFICER · O | ▼ Sale | 1,779 | $32.21 | $57K | -1.7% | plan · 2 tranches |
| Feb 4, 2026 | REED ELIZABETH EChief Legal Officer and GC · O | ▼ Sale | 2,994 | $32.18 | $96K | -2.8% | plan · 2 tranches |
| Feb 3, 2026 | Cline Christopher R.CHIEF FINANCIAL OFFICER · O | ▼ Sale | 7,242 | $32.12 | $233K | -6% | — |
| Feb 3, 2026 | Inrig JulaCHIEF MEDICAL OFFICER · O | ▼ Sale | 6,956 | $32.12 | $223K | -6.1% | — |
| Feb 3, 2026 | Calvin SandraSVP, CHIEF ACCOUNTING OFFICER · O | ▼ Sale | 4,333 | $32.12 | $139K | -8.1% | — |
| Feb 3, 2026 | Heerma PeterCHIEF COMMERCIAL OFFICER · O | ▼ Sale | 7,310 | $32.12 | $235K | -5.3% | — |
| Feb 3, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER · O·D | ▼ Sale | 100,087 | $32.28 | $3.2M | -18.8% | plan · 2 tranches |
| Feb 3, 2026 | ROTE WILLIAM E.Chief Research Officer · O | ▼ Sale | 12,446 | $32.87 | $409K | -10.2% | plan |
| Feb 3, 2026 | REED ELIZABETH EChief Legal Officer and GC · O | ▼ Sale | 7,175 | $32.12 | $230K | -6.2% | — |
| Jan 27, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER · O·D | ▼ Sale | 60,000 | $30.09 | $1.8M | -12.5% | plan · 2 tranches |
| Jan 20, 2026 | REED ELIZABETH EChief Legal Officer and GC · O | ▼ Sale | 10,000 | $27.34 | $273K | -10% | plan |
| Jan 6, 2026 | Inrig JulaCHIEF MEDICAL OFFICER · O | ▼ Sale | 2,476 | $39.74 | $98K | -2.8% | plan · 2 tranches |
| Dec 24, 2025 | Inrig JulaCHIEF MEDICAL OFFICER · O | ▼ Sale | 15,000 | $42 | $630K | -14.5% | plan |
| Dec 24, 2025 | Calvin SandraSVP, CHIEF ACCOUNTING OFFICER · O | ▼ Sale | 7,402 | $40 | $296K | -16.2% | plan |
| Dec 24, 2025 | Heerma PeterCHIEF COMMERCIAL OFFICER · O | ▼ Sale | 4,980 | $40 | $199K | -4.2% | plan |
| Dec 24, 2025 | ROTE WILLIAM E.Chief Research Officer · O | ▼ Sale | 60,000 | $40.1 | $2.4M | -37.2% | plan |
| Dec 15, 2025 | Calvin SandraSVP, CHIEF ACCOUNTING OFFICER · O | ▼ Sale | 2,910 | $36 | $105K | -6% | plan |
| Dec 1, 2025 | Cline Christopher R.CHIEF FINANCIAL OFFICER · O | ▼ Sale | 20,000 | $35.01 | $700K | -17.8% | plan |
| Nov 4, 2025 | Calvin SandraSVP, CHIEF ACCOUNTING OFFICER · O | ▼ Sale | 67,115 | $36 | $2.4M | -58% | plan |
| Oct 31, 2025 | Heerma PeterCHIEF COMMERCIAL OFFICER · O | ▼ Sale | 5,591 | $35 | $196K | -4.5% | plan |
Every $TVTX filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Travere Therapeutics filings can reach your inbox instead.
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $TVTX feed.